US Stock MarketDetailed Quotes
CYTH Cyclo Therapeutics
- 0.760
- +0.038+5.32%
Trading Nov 4 11:44 ET
21.81MMarket Cap-926P/E (TTM)
0.767High0.712Low6.10KVolume0.712Open0.722Pre Close4.55KTurnover0.04%Turnover RatioLossP/E (Static)28.70MShares2.11552wk High-4.25P/B12.07MFloat Cap0.59552wk Low--Dividend TTM15.88MShs Float17.750Historical High--Div YieldTTM7.62%Amplitude0.595Historical Low0.744Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Cyclo Therapeutics Stock Forum
EditorLina Guerrero
Published 10/08/2024, 05:25 PM
Cyclo Therapeutics, Inc., a biopharmaceutical company, announced today that it has entered into a material definitive agreement with Rafael Holdings, Inc., securing a new convertible promissory note worth $3 million. This agreement amends previous arrangements, extending the maturity date of existing notes and aligning them with the new note's terms.
On ...
Cyclo Therapeutics secures $3 million convertible note financing By Investing.com
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data From Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (Npc1)
https://www.moomoo.com/t/news/flash/19100681/3FJnV3zjzb
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
Cyclo Therapeutics (Nasdaq: CYTH) presented encouraging preliminary safety data from its ongoing pivotal Phase 3 study (TransportNPC™) and substudy evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) at the SSIEM Annual Symposium 2024. The TransportNPC™ study, with 104 enrolled pa...
Cyclo Therapeutics' TransportNPC(TM) Phase 3 clinical trial for Trappsol(R) Cyclo(TM) for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, I...
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease From European Patent Office
No comment yet